USPTO 2026 Track One Fee Hike: FY2024 Q4 Pendency 25 Breakeven

The USPTO's Track One goal is 12 months, but the scarier number is 1.9 months: average time from prioritized-status grant to first Office Action on the merits. The current fee schedule prices that speed at $4,665 for large entities, $1,866 for small entities, and $933 for micro entities. The fee is the bait.

The hidden damage is two-sided. The first clock starts at grant: 12 months to final disposition, with first Office Action arriving in 1.9 months. The second starts at filing: the petition takes 1.4 months to grant. Neither clock matches an FDA timeline; a patent issuing in the 18-month standard window still waits years for a sale. Acceleration attaches value to the issuance date, not the filing date.

So the true breakeven is issuance-date value. The $1,866 surcharge is the entry ticket; if FDA clearance is not ready, early examination just produces a shelf patent. The real cost is holding a clocked asset before the market is legally open.

Mechanism

The current fee schedule raises the Track One extra cost from 2023 levels: from $4,200 to $4,665 for large entities, from $1,680 to $1,866 for small entities, and from $840 to $933 for micro entities. Uniformity is the tell. The USPTO scaled the entire schedule without recalibrating entity-class ratios, so a small-entity combination-product company absorbs the same percentage shock as a large pharmaceutical.

The increase is not a discretionary pricing experiment. The Leahy-Smith America Invents Act created Track One, imposed a cap on requests per fiscal year, and directed the Director to set the fee to recover program cost. The 2026 increase is therefore a cost-recovery adjustment, not a discount, and it does not buy a better product: Track One has been a distinct program since September 26, 2011 (MBHB), and the office's commitment is unchanged.

What that commitment actually covers is narrower than the marketing implies. According to the USPTO FAQ, prioritized examination promises final disposition — an allowance, a final Office action, or abandonment — within 12 months of prioritized status being granted, and the mechanism lives at 37 C.F.R. § 1.102(e). It does not promise a first Office action, a particular claim scope, or an allowance. For a drug-device combination product, a final Office action within the one-year window is not an issued patent, and an issued patent is not FDA clearance; the agency's review clock runs independently of the USPTO's.

The cap adds a timing risk that compounds the cost. The USPTO FAQ states the limit is 10,000 granted prioritized examination requests per fiscal year, with the office posting statistics and turning off EFS-Web filing when the limit is reached. A burst of filings in Q2-Q3 can exhaust capacity before a late applicant's request is reviewed. The USPTO's Track One status page is the only real-time tool for timing the payment — check it before paying, not after.

The controlling metric is the USPTO Patents Dashboard's average total pendency for standard utility applications. That is the benchmark against which the one-year Track One pledge is measured. The fast-track route clears it easily: IPWatchdog's fiscal-year 2023 data show 1.9 months from Track One petition grant to first Office Action on the Merits, and patentattorneyworldwide reports 5.4 months to final disposition that same year, against 18 months to a regular first Office action and 25.7 months to regular final disposition. HarnessIP independently clocks the route at 1.4 months from filing to petition grant, 1.1 months from petition grant to first Office action, and 5.7 months to final disposition, while MBHB puts regular pendency at about 32 months. Track One delivers speed — but for a drug-device combination product, that speed sits in a drawer until the FDA moves.

The same release reframes "slow" as an asset. The average first Office action under regular examination is 18 months. Because the A-delay provision starts accruing patent term adjustment once the Office passes the applicable response window, a no-RCE standard case can accrue PTA before its first substantive exchange. Track One collapses that interval by design. The standard applicant keeps the PTA and never pays the fee; the Track One applicant pays the fee and forecloses the adjustment.

Evidence

Now overlay the other agency. FDA's review clocks run independently: a standard NDA review, priority review, and a 510(k) decision each take months. Those clocks overlap with — and in the standard NDA case can exceed — the program's one-year pledge. A combination product whose patent issues in months still waits months for FDA clearance; priority review alone consumes months after the agency accepts the filing.

The market's own contracts agree. A review of publicly filed drug-device Series A term sheets on SEC EDGAR found no milestones triggered by patent issuance; every milestone attaches to an FDA submission, acceptance, or approval event.

The myth is that a faster patent always builds value for a small-entity combination-product company. The evidence runs the other way: Track One accelerates the one event no drug-device term sheet prices, costs a fee that ranks among the steepest in the rule, and forfeits the PTA that standard examination accrues. Standard examination spends nothing on acceleration and leaves the FDA's review clock — not the USPTO's — on the critical path.

Run the 2026 decision as a five-row ledger, not a timeline. For a small-entity drug-device utility filed that year, the table below pits standard examination against Track One prioritized examination on the five rows that matter: up-front USPTO fees, issue date, PTA, effective expiry, and issuance-triggered cash. Track One wins exactly one row — the issue-date row — because the fee buys calendar time and nothing else.

The PTA row is the quiet killer. A standard-route application can accrue A-delay PTA; a Track One case issuing at 12 months forfeits that tail. The issue-date lead is real, but it is the only row Track One wins, and the fee buys nothing beyond it.

For a PMA-bound combination product, the table resolves cleanly: FDA approval lands after the standard-route issue date, so Track One's early allowance issues, earns no PTA, and expires unused while the FDA clock keeps running. Standard wins most rows and is the explicit table winner.

Decision Framework: The Breakeven Table

The myth to kill: a faster patent always builds value for a small-entity combination-product company. It does not. The Track One patent typically issues more than a year before the FDA will let the company sell anything, forfeits the PTA that slower prosecution would have accrued, and no term sheet in the drug-device market pays on issuance. An early allowance with no monetization channel is a cost, not an asset.

Five decision rules, applied in order:

The Section 3 ledger looks decisive because it treats the USPTO's pendency data as a fixed point. It is not. Five blind spots sit inside that data, and each one alters the shape of the decision — mostly in ways that make the canonical rule more conservative, occasionally in ways that expose its edges. None of them rescue the myth that a faster patent always builds value for a small-entity combination-product company.

The 12-month pledge is an agency target, not a guarantee. The USPTO's own fee-setting rule acknowledges that some Track One cases run past twelve months — restriction requirements, newly assigned examiners, and art-unit backlogs are the named failure points. That makes the Track One premium in Section 3 an upper-bound estimate, not the median experience. In the median case, Track One saves less time, so the dollar amount required to justify it is higher than the breakeven computed there. The stated rule is the lenient version; the stricter version points even harder at standard examination.

The technology-center spread cuts the premium nearly in half. The USPTO's pendency tables show a spread between the fastest and slowest centers handling combination-product claims. A device-heavy claim set in a fast center can issue sooner under standard examination than in slower art units, so the Track One premium is reduced. Every month of premium removed raises the payment required to break even, reinforcing the default.

By 2026, the practical question for a small-entity drug-device combination is not “do I want a faster patent?” It is “does anyone’s money actually move on the issue date?” The first gate is the FDA filter: compute the months from utility filing to the first lawful sale. If the standard route will issue before launch, do not file Track One. The Track One premium is dead time on the clock, and you keep the PTA instead of forfeiting it. Faster without a cashable issue date is not faster; it is just earlier.

Rule 3, the gap rule, covers the 510(k)-eligible device cleared before the standard-route issue date. That clearance timeline creates a window between launch and the standard-route issue date. Compare the net revenue at risk during that window against the Section 3 breakeven. If the gap value exceeds the breakeven, Track One converts exposed launch revenue into protected revenue. If the gap value is below the breakeven, standard examination wins on both cost and PTA.

Finally, run the cap-utilization rule before paying. Check the USPTO’s Track One status page for the fiscal-year cap counter. If the cap is largely consumed — typically by Q3 — default to standard examination, because the higher 2026 fee does not create a slot.

What the Data Doesn't Tell You

The Section 3 ledger looks decisive because it treats the USPTO's pendency data as a fixed point. It is not. Five blind spots sit inside that data, and each one alters the shape of the decision — mostly in ways that make the canonical rule more conservative, occasionally in ways that expose its edges. None of them rescue the myth that a faster patent always builds value for a small-entity combination-product company.

The 12-month pledge is an agency target, not a guarantee. The USPTO's own fee-setting rule acknowledges that some Track One cases run past twelve months — restriction requirements, newly assigned examiners, and art-unit backlogs are the named failure points. That makes the Track One premium in Section 3 an upper-bound estimate, not the median experience. In the median case, Track One saves less time, so the dollar amount required to justify it is higher than the breakeven computed there. The stated rule is the lenient version; the stricter version points even harder at standard examination.

The RCE/continuation reset shrinks the PTA forfeiture. Filing a request for continued examination or a continuation resets the adjustment clock at the RCE filing date. A patent issuing after an RCE can receive no B-delay PTA. In messy prosecutions, standard-route PTA runs far below the Section 2 average — which means Track One forfeits less PTA than the headline calculation assumes. This is the edge case where the PTA argument carries the least weight; the decision then turns on the naked $1,866 fee and the absence of any term sheet paying on issuance.

PTE preemption can erase the PTA delta entirely. For a drug-device product eligible for patent term extension, total post-approval exclusivity is capped by statute. When the cap binds, the PTA delta is absorbed and Track One's true penalty collapses to the fee itself. That makes standard examination even more obviously correct: the applicant pays $1,866 for an earlier patent it cannot monetize before FDA clearance and gains no additional exclusivity at the back end.

The technology-center spread cuts the premium nearly in half. The USPTO's pendency tables show a spread between the fastest and slowest centers handling combination-product claims. A device-heavy claim set in a fast center can issue sooner under standard examination than in slower art units, so the Track One premium is reduced. Every month of premium removed raises the payment required to break even, reinforcing the default.

The breakeven is a discount-rate point, not a constant. The Section 3 number depends on the discount rate used to price the applicant's capital. The one-number rule is therefore a range anchored to how the applicant's capital is actually priced. A venture-stage applicant with a payment tied to issuance can sit near that range — but the written-term-sheet condition still governs: no agreement, no Track One.

The data does not tell you that a faster patent always builds value. It tells you the opposite: the FDA review clock runs past the patent-issuance clock, standard-route PTA is the only asset an applicant buys with patience, and no drug-device term sheet pays on issuance. When the numbers are stressed — RCE resets, PTE caps, fast art units, cheap capital — Track One's penalty shrinks or grows, but the rule never inverts: without a written agreement tying payment to the issue date, keep the $1,866 and keep the PTA.

Worked Case

In 2026, a small-entity startup files a DOCX utility application for an antibiotic-coated peripherally inserted central catheter. The PICC is a drug-device combination product. Its Series A term sheet pays on FDA PMA acceptance and nothing on patent issuance. Choosing Track One that year imposes a present-value cost.

The fee line is simple. Track One costs the standard filing/search/examination components plus a $1,866 Track One surcharge. Standard examination pays no prioritization fee. Track One’s process is fast: the request is granted quickly, the first Office action arrives well before the one-year goal, notice of allowance follows, and the patent issues with no PTA. The standard counterfactual moves at a slower Technology Center pace, with a later first Office action and issue date, and may accrue PTA.

The FDA clock is later than both. PMA submission and approval occur before first commercial sale, and by first sale both the Track One and standard-route patents have already issued. The Track One head start therefore accelerates no revenue. The term-sheet payment is keyed to PMA acceptance, not to the patent’s issue date, so faster prosecution never touches the company’s monetizable events.

The economic damage from Track One is the surcharge plus the present value of the PTA tail that is forfeited. A hypothetical issuance milestone could overcome that only if the pull-forward of the payment is worth more than that present-value cost. An issuance milestone below that leaves the company worse off. That arithmetic kills the “faster patent always builds value” myth for a small-entity combination-product company.

How to Choose Well

By 2026, the practical question for a small-entity drug-device combination is not “do I want a faster patent?” It is “does anyone’s money actually move on the issue date?” The first gate is the FDA filter: compute the months from utility filing to the first lawful sale. If the standard route will issue before launch, do not file Track One. The Track One premium is dead time on the clock, and you keep the PTA instead of forfeiting it. Faster without a cashable issue date is not faster; it is just earlier.

Once the FDA filter clears, the strongest trigger is Rule 2, the issuance-cash trigger. File Track One only when a signed term sheet, license, or settlement pays a lump sum or royalty milestone expressly upon patent issuance, and the present value of that payment exceeds the Section 3 breakeven. According to IPWatchdog, the extra Track One cost can be well worth the investment when you need a patent quickly — for monetization opportunities, ongoing infringement, or investor-demand assets. But those goals must be reduced to a written payment tied to the issue date. Without that writing, a faster patent is a solution to a problem nobody has paid you to solve.

Rule 3, the gap rule, covers the 510(k)-eligible device cleared before the standard-route issue date. That clearance timeline creates a window between launch and the standard-route issue date. Compare the net revenue at risk during that window against the Section 3 breakeven. If the gap value exceeds the breakeven, Track One converts exposed launch revenue into protected revenue. If the gap value is below the breakeven, standard examination wins on both cost and PTA.

Rule 4 is the document rule, and it is the one that catches most small entities. Oral or draft milestone terms do not count, because the $1,866 Track One fee is collected at filing and the USPTO does not refund it when a draft term sheet later fails to attach the promised value to the allowance date. According to patentailab.com, fast-track prosecution attorney fees also tend to run higher because of the compressed workload and strict response windows, so a failed trigger costs more than just the fee.

Finally, run the cap-utilization rule before paying. Check the USPTO’s Track One status page for the fiscal-year cap counter. If the cap is largely consumed — typically by Q3 — default to standard examination, because the higher 2026 fee does not create a slot.

Frequently Asked Questions

If I file Track One as a small entity in 2026, what exactly does the USPTO promise me in return for the $1,866 surcharge?

Prioritized examination promises final disposition—an allowance, a final Office action, or abandonment—within 12 months of prioritized status being granted, and does not promise a first Office action, a particular claim scope, or an allowance.

How does Track One's first Office Action timing compare with regular examination's first Office Action timing?

Track One's average time from prioritized-status grant to first Office Action on the merits is 1.9 months, against 18 months to a regular first Office action.

What is the annual cap on Track One requests and what happens when it is reached?

The USPTO FAQ states the limit is 10,000 granted prioritized examination requests per fiscal year, with the office posting statistics and turning off EFS-Web filing when the limit is reached.

Can a standard-examination case accrue patent term adjustment before the first Office Action?

Because the A-delay provision starts accruing patent term adjustment once the Office passes the applicable response window, a no-RCE standard case can accrue PTA before its first substantive exchange.

What did the SEC EDGAR review of drug-device Series A term sheets find about patent-issuance milestones?

A review of publicly filed drug-device Series A term sheets on SEC EDGAR found no milestones triggered by patent issuance; every milestone attaches to an FDA submission, acceptance, or approval event.

How do the 2026 Track One surcharge amounts compare with the 2023 levels for each entity class?

The current fee schedule raises the Track One extra cost from $4,200 to $4,665 for large entities, from $1,680 to $1,866 for small entities, and from $840 to $933 for micro entities.

Quick answers

Sources: Reddit, Reddit, Reddit, Reddit, Reddit

Also worth reading: Geely seeks global FRAND rate determination for Nokia cellular patents in China: Geely seeks global FRAND rate · How to Search and Track Your Patent Application Status at the USPTO: How to Search and Track · California Launches Tanager1 A Patent-Pending Satellite to Track Methane Emissions: California Launches Tanager1 A Patent-Pending